Previous Article | Next Article 
Journal of Clinical Microbiology, October 2007, p. 3436-3438, Vol. 45, No. 10
0095-1137/07/$08.00+0 doi:10.1128/JCM.00973-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Human Immunodeficiency Virus Type 1 (HIV-1) Plasma Load Discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assays
F. Damond,1*
B. Roquebert,1
A. Bénard,2
G. Collin,1
M. Miceli,1
P. Yéni,3
F. Brun-Vezinet,1 and
D. Descamps1
Laboratoire de Virologie, Hôpital Bichat Claude Bernard, Paris, France,1
INSERM U593, ISPED Bordeaux F33076, France,2
Service Maladies Tropicales et Infectieuses, Hopital Bichat Claude Bernard, Paris, France3
Received 10 May 2007/
Returned for modification 11 July 2007/
Accepted 27 July 2007

ABSTRACT
We compared plasma viral load values obtained with COBAS AMPLICOR
human immunodeficiency virus type 1 (HIV-1) MONITOR version
1.5 and with COBAS TaqMan HIV-1 assays. Mean values were 4.2
and 2.9 log
10 copies/ml, respectively, showing the lack of agreement
between the two assays.

TEXT
Plasma RNA viral load quantification is a clinically validated
tool for monitoring human immunodeficiency virus type 1 (HIV-1)
infection (
5). There are several commercially available PCR
assays for HIV-1 RNA quantification. Most of them were recently
automated for sample preparation and were coupled to a real-time
PCR-based method, giving a broader range of HIV-1 quantification
and fewer time-consuming manipulations (
2,
4,
6). Since June
2006, the 4,000 HIV-1-infected patients managed in the Department
of Infectious Diseases of Bichat Claude Bernard Hospital (Paris,
France), whose viral loads had previously been assayed with
the COBAS AMPLICOR HIV-1 MONITOR version 1.5 method (Roche Diagnostics
Systems, Inc., Branchburg, NJ) and by automated extraction with
the Magnapure large-volume kit (Roche Diagnostics, Meylan, France),
have been monitored with the new RealTime COBAS TaqMan HIV-1
system assay, as recommended by the manufacturer. However, we
were puzzled by significant discrepancies (more than 0.5 log
10 copies/ml) between the two assays of serial plasma samples from
patients not taking antiretroviral therapy.
We therefore compared HIV-1 RNA values obtained with the COBAS AMPLICOR HIV-1 MONITOR version 1.5 with those of the COBAS TaqMan HIV-1 assay in the routine clinical setting.
Plasma EDTA samples stored at –80°C were tested in parallel with the COBAS AMPLICOR MONITOR 1.5 assay (still available in our laboratory) and the COBAS TaqMan HIV system. Moreover, samples from all untreated patients with HIV-1 RNA values below 5,000 copies/ml with the COBAS TaqMan HIV system were also tested with the COBAS AMPLICOR HIV-1 MONITOR 1.5 assay. The HIV-1 subtypes were determined in all the patients by examining the relatedness of the pol sequences with reference sequences of HIV-1 genetic subtypes and circulating recombinant forms obtained from the Los Alamos database (http://hiv-web.lanl.gov). Mean values (log10 copies/ml) obtained with the two assays were compared with a t test for paired data. Discrepancies between the two assays were examined individually for each HIV-1 subtype by using the Kruskal-Wallis test. Statistical analyses were done with SAS version 8.2 software (SAS Institute Inc., Cary, NC), and P values of less than 0.05 were considered to indicate significant differences. Bland and Altman curves were used to represent the degree of agreement between the two techniques (Fig. 1).
The HIV-1 plasma viral load was determined with both assays,
using 160 plasma specimens obtained from 140 patients. The mean
values (± standard deviation [SD]) were 2.99 log copies/ml
(±1.13) and 2.51 log copies/ml (±0.80), respectively,
with the COBAS AMPLICOR HIV-1 MONITOR 1.5 assay and the COBAS
TaqMan HIV system (Fig.
1). Among the 140 patients in whom viral
load was determined with both assays, discrepancies of more
than 0.5 log copies/ml were observed for 34 cases (24%). These
patients were infected by subtypes A (
n = 4), B (
n = 9), D (
n = 1), CRF_02 (
n = 15), CRF_13cpx (
n = 1), F (
n = 1), and G (
n = 3). The viral loads obtained with the 54 plasma samples from
these 34 patients are summarized in Table
1. The mean values
obtained with the COBAS TaqMan System and the COBAS AMPLICOR
HIV-1 MONITOR 1.5 assay were 2.9 (±0.54) and 4.2 log
10 (±0.82) copies/ml, respectively. The mean values obtained
with the two assays differed by 1.3 log
10 copies/ml (
P <
0.0001). The viral load distributions obtained for B versus
non-B subtypes did not differ significantly between the two
assays (
P = 0.32).
Significant differences in viral load quantification, therefore,
exist between these commercial assays from the same manufacturer.
It has previously been shown that HIV genetic diversity can
influence plasma HIV-1 RNA quantification in patients infected
by non-B subtypes, and several authors have reported the failure
of commercial assays for viral load monitoring in patients infected
by non-B subtypes (
1,
3,
4). This finding led the manufacturer
to adapt the COBAS MONITOR version 1.0 assay to accept a broader
range of viral diversity. Our results show that the COBAS TaqMan
HIV-1 system underquantifies not only divergent subtypes like
CRF_02 but also HIV-1 subtype B. Recently, Gueudin et al. reported
that viral load values obtained with the COBAS TaqMan system
were 0.28 log
10 lower on average than those obtained with the
COBAS MONITOR version 1.5 assay: 23 (26%) of 88 patients had
more than a 0.5 log
10 difference between the values of the two
methods, and nine had a difference exceeding 1 log
10 copies/ml
(
4). It is noteworthy that the primers designed for the COBAS
TaqMan system are located in the same highly conserved
gag region
of the HIV-1 genome as in the COBAS MONITOR 1.5 assay (
6) (
7).
The most likely explanation for these differences in HIV-1 RNA
quantification is a COBAS TaqMan system primer or probe mismatch.
A problem during the automated nucleic acid extraction procedure
on the COBAS AmpliPrep instrument is unlikely, as this would
occur at random. Moreover, the discrepancies found here are
not due to a problem with a particular lot, as several lots
have been used in our laboratory since June 2006. However, we
cannot rule out a problem with several lots, as these differences
in HIV-1 quantification between the two assays were not observed
during the premarketing evaluation of the COBAS TaqMan system
(
6). Indeed, during the initial evaluation, we tested 112 plasma
samples from patients infected by HIV-1 subtype B (
n = 54) and
by various HIV-1 non-B subtypes (
n = 58). We have also observed
differences of more than 0.5 log
10 copies/ml between the values
of the two assays. These differences concerned seven plasma
samples (7/112; 6%), as follows: COBAS MONITOR 1.5 > COBAS
TaqMan (
n = 5) and COBAS TaqMan > COBAS MONITOR 1.5 (
n =
2). The frequency of discordant results from the initial evaluation
was lower (6%) than that from the study presented here (25%).
One possible explanation is that the kit used during the initial
evaluation (C-
Taq HIV-1 IVD
+) was different from the one delivered
by Roche after 2006 (CAP CTM HIV-1 IVD
+).
These results question the reliability of the RealTime COBAS TaqMan system for viral load quantification in HIV-1-infected patients. They also underline the importance of primer and probe design for real-time PCR quantification of viruses with high genetic diversity. Finally, they stress the need to harmonize viral load assays used in therapeutic trials.

FOOTNOTES
* Corresponding author. Mailing address: Laboratoire de Virologie, Hôpital Bichat Claude Bernard, 75018 Paris, France. Phone: 33 1 40 25 61 51. Fax: 33 1 40 25 67 69. E-mail:
florence.damond{at}bch.aphp.fr 
Published ahead of print on 22 August 2007. 

REFERENCES
1 - Alaeus, A., K. Lidman, A. Sonnerborg, and J. Albert. 1997. Subtype-specific problems with quantification of plasma HIV-1 RNA. AIDS 11:859-865.[CrossRef][Medline]
2 - Berger, A., L. Scherzed, M. Sturmer, W. Preiser, H. W. Doerr, and H. F. Rabenau. 2002. Evaluation of the COBAS AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitor test (manual specimen preparation). J. Clin. Virol. 25(Suppl. 3):S103-S107.[CrossRef][Medline]
3 - Damond, F., C. Apetrei, D. Descamps, F. Brun-Vezinet, and F. Simon. 1999. HIV-1 subtypes and plasma RNA quantification. AIDS 13:286-288.[Medline]
4 - Gueudin, M., J. C. Plantier, V. Lemee, M. P. Schmitt, L. Chartier, T. Bourlet, A. Ruffault, F. Damond, M. Vray, and F. Simon. 2007. Evaluation of the Roche Cobas TaqMan and Abbott RealTime Extraction-Quantification systems for HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 44:500-505.[CrossRef][Medline]
5 - Mellors, J. W., A. Munoz, J. V. Giorgi, J. B. Margolick, C. J. Tassoni, P. Gupta, L. A. Kingsley, J. A. Todd, A. J. Saah, R. Detels, J. P. Phair, and C. R. Rinaldo, Jr. 1997. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946-954.[Abstract/Free Full Text]
6 - Schumacher, W., E. Frick, M. Kauselmann, V. Maier-Hoyle, R. van der Vliet, and R. Babiel. 2007. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 38:304-312.[CrossRef][Medline]
7 - Sninsky, J. J., and S. Kwok. 1993. The application of quantitative polymerase chain reaction to therapeutic monitoring. AIDS 7(Suppl. 2):S29-S34.[Medline]
Journal of Clinical Microbiology, October 2007, p. 3436-3438, Vol. 45, No. 10
0095-1137/07/$08.00+0 doi:10.1128/JCM.00973-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Delaugerre, C., Denis, B., Peytavin, G., Palmer, P., Mourez, T., Le Goff, J., Molina, J.-M., Simon, F.
(2009). Clinical and Resistance Consequences of Misquantification of Plasma and Cerebrospinal Fluid Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Samples from an HIV-1 Subtype G-Infected Patient. J. Clin. Microbiol.
47: 3763-3764
[Abstract]
[Full Text]
-
Scott, L. E., Noble, L. D., Moloi, J., Erasmus, L., Venter, W. D. F., Stevens, W.
(2009). Evaluation of the Abbott m2000 RealTime Human Immunodeficiency Virus Type 1 (HIV-1) Assay for HIV Load Monitoring in South Africa Compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 Assays. J. Clin. Microbiol.
47: 2209-2217
[Abstract]
[Full Text]
-
Wirden, M., Tubiana, R., Marguet, F., Leroy, I., Simon, A., Bonmarchand, M., Ait-Arkoub, Z., Murphy, R., Marcelin, A. G., Katlama, C., Calvez, V.
(2009). Impact of Discrepancies between the Abbott RealTime and Cobas TaqMan Assays for Quantification of Human Immunodeficiency Virus Type 1 Group M Non-B Subtypes. J. Clin. Microbiol.
47: 1543-1545
[Abstract]
[Full Text]
-
Sloma, C. R., Germer, J. J., Gerads, T. M., Mandrekar, J. N., Mitchell, P. S., Yao, J. D. C.
(2009). Comparison of the Abbott RealTime Human Immunodeficiency Virus Type 1 (HIV-1) Assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test: Workflow, Reliability, and Direct Costs. J. Clin. Microbiol.
47: 889-895
[Abstract]
[Full Text]
-
Korn, K., Weissbrich, B., Henke-Gendo, C., Heim, A., Jauer, C. M., Taylor, N., Eberle, J.
(2009). Single-Point Mutations Causing More than 100-Fold Underestimation of Human Immunodeficiency Virus Type 1 (HIV-1) Load with the Cobas TaqMan HIV-1 Real-Time PCR Assay. J. Clin. Microbiol.
47: 1238-1240
[Abstract]
[Full Text]
-
Holguin, A., Lopez, M., Molinero, M., Soriano, V.
(2008). Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. J. Clin. Microbiol.
46: 2918-2923
[Abstract]
[Full Text]
-
Yao, J. D. C., Germer, J. J., Damond, F., Roquebert, B., Descamps, D.
(2008). Plasma Load Discrepancies between the Roche Cobas Amplicor Human Immunodeficiency Virus Type 1 (HIV-1) Monitor Version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Assays. J. Clin. Microbiol.
46: 834-834
[Full Text]